Serum Allograft Inflammatory Factor 1 Concentrations and Metabolic Parameters in Patients with Type 2 Diabetes Mellitus
Presentation Number: MON 637
Date of Presentation: April 3rd, 2017
Shaimaa Samir Mashal*1, Fouad Khalifa Harras2, Loai Mohamed Elahwal3 and Manal Abd Elwahed Eid4
1Tanta University Faculty of Medicine, Tanta, Egypt, 2Tanta University, Tanta, Egypt, 3Tanta University, Faculty of Medicine, Tanta, Egypt, 4Faculty of Medicine, Tanta, Egypt
Introduction: Exposure to the diabetic environment induces macrophages to synthesize a variety of molecules that can cause renal injury, progression of inflammation and atherogenesis. Recent studies highlight the need for antimacrophage therapies in diabetic patients and have implicated Allograft inflammatory factor-1 (AIF-1) as a marker of activated macrophages.
Aim of the present research: was to evaluate the level of Serum Allograft Inflammatory Factor-1 (AIF-1) and its correlations with clinical and biochemical parameters in patients with type 2 diabetes.
Subjects and methods:80 patients with type 2 Diabetes Mellitus and 20 control subjects were enrolled in this study .All were subjected to history taking, clinical examination, routine laboratory investigations, Enzyme-linked immunosorbent assay was used to measure serum AIF-1then we assessed in patients with type 2 diabetes the correlations and relations of serum AIF-1 to various metabolic and clinical parameters.
Results: Serum AIF-1 concentrations in type 2 diabetic patients were significantly increased compared to healthy subjects (Mean ± SD 4037.13 ± 4702.11 vs. 255.50 ± 210.97, P. value 0.001), and were directly correlated with age, FPG, PPPG, serum triglycerides, blood urea, serum creatinine and spot urine albumin creatinine ratio, whereas the serum AIF-1 concentrations inversely correlated with HDL and eGFR. Serum AIF-1 concentrations were significantly increased in severely hypertensive and hypertensive patients, P value (0.010). Serum AIF1 concentrations were significantly increased in Non Proliferative Diabetic Retinopathy (NPDR) either alone or associated with Macular Oedema, (mean serum AIF-1 was 5253.00), with a significant relationship in patients with diabetic nephropathy, (mean serum AIF-1 was 5648.82).Serum AIF-1 concentrations did not correlated to BMI, hbA1c or serum uric acid. No significant relationship between serum AIf-1 and diabetic neuropathy or line of treatment.
Conclusions: Increased serum AIF-1 in patients with type 2 diabetes may serve as a biomarker or a new therapeutic target in patients with diabetic nephropathy and retinopathy.
Nothing to Disclose: SSM, FKH, LME, MAEE